Raymond James Rates Hinge Health (HNGE) buy, $80 Price Target

Analyst Brian Peterson of Raymond James keeps a buy rating on Hinge Health, setting an $80.00 target for the digital musculoskeletal care provider, a 15.24% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 2:01 PM EDT · Updated Jun 22, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Raymond James rated Hinge Health, Inc. ($HNGE) "buy" with a $80 price target on June 15, 2026.

Since the rating, $HNGE is up 0.7% after 1 week, up 25.5% after 1 month and up 45.1% to date (from the $68.35 close on Jun 15, 2026).

HNGE Hinge Health, Inc.

$99.16 +117.65% year to date

Daily close · Oct 16, 2026

Key Points

Raymond James analyst Brian Peterson reiterated a buy rating on Hinge Health, Inc. (NYSE:HNGE) on June 15, 2026, setting an $80.00 price target.
Raymond James's $80 price target implies 15.24% upside from Hinge Health, Inc.'s ($HNGE) current $69.42 share price.
The broader Wall Street analyst community holds a consensus buy recommendation on the stock with a mean price target of $112.13 across 16 opinions.
Hinge Health trades around $69.42, supported by a price-to-earnings ratio of 34.64 and a forward P/E ratio of 34.33.

Get $HNGE trade alerts by text

We text you when insiders, Congress or big funds trade $HNGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures

Raymond James Reaffirms Its View on Hinge Health

Raymond James analyst Brian Peterson reiterated a buy rating on Hinge Health, Inc. (NYSE:HNGE) on June 15, 2026, setting an $80.00 price target. The call comes as the digital care provider continues to expand its footprint in the healthcare technology sector by automating musculoskeletal therapy for self-insured employers.

Analysts Set New Price Targets

Wall Street firms have remained active in updating their views on the health technology provider in recent months. On October 16, 2026, Keybanc maintained an overweight rating with a $140.00 price target, moving up from a prior target of $125.00. Barclays holds an overweight rating with a $110.00 target set on October 12, 2026, advancing from its previous $100.00 objective. Needham maintains a buy rating alongside a $115.00 target on September 30, 2026, following an earlier target of $97.00. Baird maintains a neutral rating with a $90.00 target on September 22, 2026, up from $85.00. Stifel keeps a buy rating and a $115.00 target as of September 8, 2026, moving from $96.00. Truist Securities maintains a buy rating with a $112.00 target set on August 11, 2026, rising from $85.00. RBC Capital maintains an outperform rating with a $110.00 target on August 5, 2026, up from $75.00, while Citizens maintains a market outperform rating with a $107.00 target on the same day. Overall, the stock carries a consensus buy recommendation with a mean price target of $112.13 across 16 analyst opinions.

Stock Valuation and Market Standing

Hinge Health shares trade at $69.42, sitting well below its 52-week high of $107.00 and above its 52-week low of $30.08. The company carries a market capitalization of roughly $8.47 billion and operates with a price-to-earnings ratio of 34.64, alongside a forward P/E ratio of 34.33. Investors are also eyeing Hinge Health's next earnings report scheduled for November 2, 2026, for further updates on adoption rates and platform expansion.

12-month forecast

$HNGE price target

Hinge Health, Inc. daily closes and this analyst's $80 target. Not advice.

Technology and Care Delivery Platform

Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care, including acute injury, chronic pain, and post-surgical rehabilitation, primarily serving self-insured employers through personalized care tools.

What to Watch Next for HNGE

Market participants will monitor upcoming analyst updates and corporate milestones leading up to the November earnings release. As a reiteration rather than a fresh corporate event, today's update reflects ongoing sentiment among coverage providers without altering reported share counts or fundamental balance sheet metrics.